Zhang, J., Lu, P., Zhao, H., Chen, J., Shi, W., Ren, X., . . . Ma, X. Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. BMJ Publishing Group.
Chicago Style (17th ed.) CitationZhang, Jian, et al. Camrelizumab Plus Carboplatin and Pemetrexed as First-line Therapy for Advanced Non-squamous Non-small-cell Lung Cancer: 5-year Outcomes of the CameL Randomized Phase 3 Study. BMJ Publishing Group.
MLA (9th ed.) CitationZhang, Jian, et al. Camrelizumab Plus Carboplatin and Pemetrexed as First-line Therapy for Advanced Non-squamous Non-small-cell Lung Cancer: 5-year Outcomes of the CameL Randomized Phase 3 Study. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.